KDM6B and central nervous system cancer: For example, recent work published in Nature Cancer revealed that inhibiting KDM6B epigenetically reprograms cytokine networks, shifting macrophages from immunosuppressive to immunostimulatory phenotypes and sensitizing gliomas to PD-1 checkpoint blockade.